Merck & Co., Inc. (NYSE:MRK) BofA Securities 2024 Health Care Conference May 15, 2024 4:40 PM ET Company Participants Caroline Litchfield - EVP & CFO Conference Call Participants Geoff Meacham - Bank of America Securities Geoff Meacham [Call Starts abruptly] Caroline Litchfield, CFO. Caroline, good to see you. Caroline Litchfield Great to see you again too. Geoff Meacham Thanks for joining. I know we have a list of questions, but maybe just kind of give us the post 1Q highlights and kind of how you see mayb ...

The Cigna Group (NYSE:CI) BofA Securities 2024 Health Care Conference Call May 15, 2024 2:40 PM ET Company Participants Brian Evanko - CFO of The Cigna Group, President and CEO of Cigna Healthcare Hasan Riaz - Lead Principal, Investor Relations Ralph Giacobbe - Head of Investor Relations Conference Call Participants Kevin Fischbeck - Bank of America Kevin Fischbeck All right. I want to thank everyone for joining us today. It's my pleasure to be hosting The Cigna Group. Presenting today, we have Brian Evanko ...

Editas Medicine, Inc. (NASDAQ:EDIT) RBC Capital Markets Global Healthcare Conference Call May 15, 2024 2:05 PM ET Company Participants Gilmore O’Neill - Chief Executive Officer Conference Call Participants Luca Issi - RBC Capital Markets Luca Issi Thanks, everybody. Luca Issi, senior biotech analyst here at RBC Capital Markets. Today is our great privilege to have Editas for us with us with a fireside chat. Representing the company, we have Gilmore O’Neill, Chief Executive Officer. Gilmore thanks so much fo ...

Affirm Holdings, Inc. (NASDAQ:AFRM) Barclays 14th Annual Emerging Payments and FinTech Forum May 15, 2024 2:25 PM ET Company Participants Brooke Major-Reid - Chief Capital Officer Robert O'Hare - SVP, Finance Conference Call Participants Ramsey El-Assal - Barclays Ramsey El-Assal All right. Our next fireside chat of the day is with the Brooke Major-Reid, Chief Capital Officer; and Robert O'Hare, SVP Finance of Affirm. Brooke and Rob, thank you for being here again. Pleased to have you. Brooke Major-Reid Tha ...

Bristol-Myers Squibb Company (NYSE:BMY) Bank of America Global Healthcare Conference 2024 May 15, 2024 2:20 PM ET Company Participants David Elkins – Executive Vice President and Chief Financial Officer Conference Call Participants Geoff Meacham – Bank of America Chen Yang – Bank of America Geoff Meacham I’m Geoff Meacham. I’m the senior biopharma analyst, and I have Charlie from my team on stage with me as well. Welcome to the Bristol-Myers session. So on behalf of Bristol, we have CFO, David Elkins. David ...

AbbVie, Inc. (NYSE:ABBV) Conference Call Summary Company Overview - **Company**: AbbVie, Inc. - **Date**: May 15, 2024 - **Participants**: - Robert Michael - CEO - Roopal Thakkar - SVP, Chief Medical Officer, Global Therapeutics - Jeffrey Stewart - COO - **Industry**: Healthcare, specifically focusing on pharmaceuticals and biotechnology Key Points 1. Growth Platform Performance - The growth platform constitutes 80% of AbbVie's business and is experiencing mid-teens growth, contributing $5.6 billion in growth this year alone [2][3] - The company anticipates robust growth next year, projecting above industry average growth, ultimately aiming for high single-digit compound growth throughout the decade [3][5] 2. HUMIRA Erosion and Management - HUMIRA's revenue declined by approximately $6.5 billion last year and is expected to decline to about $4.5 billion this year [5] - Despite HUMIRA's erosion, AbbVie is returning to growth one year post the U.S. HUMIRA loss of exclusivity (LOE), a feat not achieved by others in the industry [5][13] 3. SKYRIZI and RINVOQ Outlook - SKYRIZI and RINVOQ are performing exceptionally well, with significant market share capture and continued momentum in inflammatory bowel disease (IBD) indications [4][6] - SKYRIZI is expected to receive UC approval mid-year, which will further enhance its growth trajectory [8] - RINVOQ is projected to expand into new indications by 2026-2028, potentially adding several billion dollars in peak revenue [9] 4. Oncology Pipeline Developments - AbbVie is focusing on its ADC (antibody-drug conjugate) pipeline, with promising programs in oncology, including ELAHERE and ABBV-400 [6][19] - The company is entering Phase III trials for ABBV-400 in colon cancer, showing greater depth of response compared to previous treatments [19][20] 5. Part D Benefit Changes - The redesign of the Part D benefit is expected to impact growth, particularly in immunology and oncology, but AbbVie has already factored this into their guidance [11][12] - The company anticipates several points of growth despite the changes, maintaining a robust growth outlook [12][13] 6. Aesthetics Business Recovery - The U.S. toxin market has returned to growth, with mid-single-digit growth observed in the first quarter [44] - AbbVie projects high single-digit growth for its aesthetics business, aiming for over $9 billion by 2029 [45][48] 7. Business Development Strategy - AbbVie is focusing on smaller-sized opportunities that can drive long-term growth, particularly in immunology and oncology [50][51] - The company is committed to maintaining a net leverage of 2x within 2-3 years while pursuing growth opportunities [52] 8. Competitive Landscape in Neuroscience - AbbVie is optimistic about its position in the neuroscience market, particularly with the development of tavapadon for Parkinson's disease [30][32] - The company believes its product profile offers advantages over competitors, enhancing its market share potential [36] 9. Market Dynamics and Share Performance - AbbVie has maintained its market share in the aesthetics segment despite competition from new entrants like DAXXIFY [44] - The company is seeing strong performance in its Juvederm family, contributing to overall share growth [45] 10. Future Growth Drivers - AbbVie is exploring innovative products, including short-acting toxins and regenerative fillers, to drive growth in the aesthetics market [48] - The company is also looking to expand its ADC capabilities and enhance its oncology portfolio through strategic investments [50][51] Conclusion AbbVie is navigating a transitional phase with the erosion of HUMIRA while focusing on its growth platforms, particularly SKYRIZI and RINVOQ. The company is optimistic about its oncology pipeline and aesthetics business recovery, with a strategic focus on smaller, high-potential opportunities for long-term growth.

Warner Bros. Discovery, Inc. (NASDAQ:WBD) MoffettNathanson's Media, Internet & Communications Conference May 15, 2024 1:00 PM ET Company Participants Gerhard Zeiler - President of International Conference Call Participants Robert Fishman - MoffettNathanson Robert Fishman It's Robert Fishman here again, and we are very excited to have a new guest for us and for most here, Gerhard Zeiler at Warner Bros. Discovery. And so instead of me just reading your bio, I thought we'd maybe just kick off with you sharing ...

CRISPR Therapeutics AG (NASDAQ:CRSP) BofA Securities 2024 Health Care Conference Call May 15, 2024 12:20 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Geoffrey Meacham - Bank of America Merrill Lynch Geoffrey Meacham All right. Here we go. Okay. Welcome to the second day of the Bank of America Health Care Conference. So my name is Geoff Meacham, I'm the senior biopharma analyst. We are thrilled today to have CRISPR Therapeutics. And speaking on behalf of ...

Corteva, Inc. (NYSE:CTVA) 2024 BMO Farm to Market Chemicals Conference May 15, 2024 9:30 AM ET Company Participants Dave Anderson - CFO Sam Eathington - CTO Kim Booth - VP, IR Conference Call Participants Joel Jackson - BMO Capital Joel Jackson Okay. Thanks. So, we'll keep going here. We're going to get into the world of seeds and crop cans. So next up is a fireside chat with Corteva who is, of course, a leading ag chem producer, very strong seed and trade portfolio and a very large crop protection producer ...

Johnson & Johnson (NYSE:JNJ) RBC Capital Markets Global Healthcare Conference May 15, 2024 11:00 AM ET Company Participants Timothy Schmid - Executive Vice President and Worldwide Chairman of MedTech Conference Call Participants Shagun Singh - RBC Capital Markets Shagun Singh We will get started. Hello everyone, and welcome to the 2024 RBC Capital Global Healthcare Conference. I’m Shagun Singh, Senior Medical Device Analyst at RBC. And I’m very pleased to have Johnson & Johnson here with us again this year. ...